Connection lost
Server error
Mylan Pharmaceuticals, Inc. v. United States Food & Drug Administration Case Brief
Why Top Law Students (And Those Aspiring to Be) Use LSD+ Briefs
Let's be real, law school is a marathon. Our exclusive Flash-to-Full case system is designed by Harvard Law School and MIT grads to match your pace: Quick summaries when you're slammed, detailed analysis when you need to go deep. Only LSD+ offers this kind of flexibility to genuinely fit your study flow.
Adaptive Case Views
Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.
Exam-Ready IRAC Format
We deliver the precise structure professors look for in exam answers.
Complex Cases, Clarified
We break down dense legal reasoning into something digestible, helping you grasp core concepts.
Case Brief Summary & Legal Analysis
tl;dr: FDA denied Mylan’s petition to block an “authorized generic” during Mylan’s 180-day exclusivity period. The court affirmed, finding the statute unambiguous and not granting FDA such power.
Legal Significance: Reinforces FDA’s interpretation of the Hatch-Waxman Act, clarifying that the 180-day exclusivity for first generic filers does not bar competition from “authorized generics” marketed by brand-name drug companies.
Mylan Pharmaceuticals, Inc. v. United States Food & Drug Administration Law School Study Guide
Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.
Case Facts & Court Holding
Key Facts & Case Background
Mylan Pharmaceuticals, Inc. (Mylan) received FDA approval for a generic version of Macrobid and was entitled to a 180-day market exclusivity period under the Hatch-Waxman Act, 21 U.S.C. § 355(j)(5)(B)(iv). Concurrently, Procter & Gamble, the brand-name drug (NDA) holder, licensed a third party, Watson Pharmaceuticals, to sell an “authorized generic” version of Macrobid. Mylan petitioned the FDA, arguing that the authorized generic could not be sold during its 180-day exclusivity period. The FDA denied Mylan’s petition, concluding the Act did not prohibit an NDA holder from marketing its own approved drug, including through an authorized generic, during this period. The FDA reasoned that the exclusivity provision only restricts subsequent Abbreviated New Drug Application (ANDA) applicants, not drugs marketed under an existing New Drug Application (NDA). Mylan sued the FDA under the Administrative Procedure Act (APA), alleging the denial was arbitrary, capricious, or contrary to law. The district court dismissed Mylan’s complaint.
Court Holding & Legal Precedent
Issue: Did the Food and Drug Administration lawfully interpret 21 U.S.C. § 355(j)(5)(B)(iv) of the Hatch-Waxman Act as not granting it the authority to prohibit the marketing of an “authorized generic” drug by an NDA holder during the 180-day exclusivity period afforded to the first generic ANDA filer?
Yes, the FDA’s interpretation was lawful. The court affirmed the dismissal, holding Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Du
IRAC Legal Analysis
Complete IRAC Analysis for Higher Grades
IRAC (Issue, Rule, Analysis, Conclusion) is the exact format professors want to see in your exam answers. Our exclusive Flash-to-Full briefs combine holding, analysis, and rule statements formatted to match what A+ students produce in exams. These structured briefs help reinforce the essential legal reasoning patterns expected in law school.
Legal Issue
Did the Food and Drug Administration lawfully interpret 21 U.S.C. § 355(j)(5)(B)(iv) of the Hatch-Waxman Act as not granting it the authority to prohibit the marketing of an “authorized generic” drug by an NDA holder during the 180-day exclusivity period afforded to the first generic ANDA filer?
Conclusion
This case affirms the FDA's narrow interpretation of the 180-day generic drug Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
Legal Rule
Agency interpretations of statutes they administer are reviewed under the *Chevron* framework. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deseru
Legal Analysis
The court applied the *Chevron* framework to review the FDA's interpretation of Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cil
Flash-to-Full Case Opinions
Flash Summary
- The FDA lacks authority under 21 U.S.C. § 355(j)(5)(B)(iv) to block